Treatments for autoimmune diseases such as lupus are often associated with multiple side-effects and a poor patient response. My research is harnessing the potential of RNA therapeutics, like those used in mRNA vaccines, to revolutionise autoimmune disease treatments, blocking disease at its source.

Learn more about my group's research

Michael Gantier

Areas of interest

COVID-19 Inflammation and cancer Influenza Lupus

Research group

Nucleic Acids and Innate Immunity

Biography

Prof Michael Gantier is a molecular and cell biologist with expertise in the field of innate immunity – the system our bodies use to detect and fight infections.

An expert in nucleic acids biology, with a strong focus on their therapeutic implications in the modulation of immunity, Prof Gantier’s research examines how pathogenic nucleic acids (such as DNA or RNA) are recognised by a series of selective sensors of the immune system.

While these sensors are normally protective, they can also misfire and initiate a vicious circle of inflammation leading to autoimmunity, when the immune system mistakenly targets the body’s own healthy cells, tissues and organs, leading to chronic inflammation and damage.

By characterising how these sensors are kept in check at the molecular level, Prof Gantier’s research opens novel therapeutic avenues to dampen the inflammation causing autoimmunity.

Prof Gantier’s team recently discovered that tiny fragments of RNAs are produced by our bodies to block inflammation sensors, and prevent autoimmunity (Nature Immunology 2026). This has led his team, in close collaboration with ASX-listed Noxopharm Ltd, to develop synthetic RNA fragments which can be used to target cutaneous (skin) lupus and psoriasis, and have recently completed a phase 1 clinical trial. These findings also have the capacity to improve emerging technologies such as mRNA vaccines.

His studies of how nucleic sensing operates at a cellular level has also led his team to discover the first clinic-ready TBK1 inhibitor, idronoxil  (Nature Communications 2023).

Prof Gantier’s focus is twofold

  1. Understanding how innate immune sensors misfire, with the goal of preventing autoimmunity.
  2. Developing a new class of anti-inflammatory molecules, known as RNA therapeutics, to blunt aberrant inflammation at its source in a wide range of diseases.

Education

Awards and fellowships

Affiliations

Publication highlights